Gene Therapy for ACM Due to a PKP2 Pathogenic Variant

Recruiting

Phase 1

Phase 2

Gene TherapyGene Therapy for ACM Due to a PKP2 Pathogenic Variant

Sponsor:

Lexeo Therapeutics

Code:

NCT06109181

Conditions

Arrhythmogenic Cardiomyopathy

PKP2-ACM

PKP2-ARVC

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

LX2020

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Lexeo Therapeutics on 2025-01-23.